3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Sarcoma
2
Colorectal Neoplasms
2
Uterine Cervical Neoplasms
1
Squamous Non-small Cell Lung Cancer
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms, Multiple Primary
1
Neoplasm Metastasis
1
NSCLC
1
Meningeal Carcinomatosis
1
Lung Neoplasms
1
Locally Advanced Rectal Carcinoma
1
Histiocytoma, Malignant Fibrous
1
HER2-positive Breast Cancer
1
Gastrointestinal Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Dermatofibrosarcoma
1
Colonic Neoplasms
1
Chondrosarcoma
1
Carcinoma, Ovarian Epithelial
1
Biliary Tract Neoplasms
1
Advanced Pancreatic Cancer
1
Interventions
Radiation Dose Hypofractionation
2
toripalimab
1
lentiviral minigene vaccine of COVID-19 coronavirus
1
envafolimab
1
brostallicin
1
anlotinib
1
Temozolomide
1
Ritonavir
1
Radiotherapy
1
Phlebotomy
1
Molecular Diagnostic Techniques
1
Microarray Analysis
1
Ipilimumab
1
Indinavir
1
Doxorubicin
1
Diathermy
1
Blood Specimen Collection
1
Biopsy, Needle
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Histiocytoma, Malignant Fibrous
×
envafolimab
×
Clear all
NCT04480502
2024-05-17
ENVASARC
Tracon Pharmaceuticals Inc.
Phase 2
Unknown
207 enrolled